首页> 美国卫生研究院文献>Journal of the Royal Society of Medicine >Randomized double-blind placebo-controlled trial of homoeopathic proving for Belladonna C30.
【2h】

Randomized double-blind placebo-controlled trial of homoeopathic proving for Belladonna C30.

机译:颠茄 C30同种疗法证明的随机双盲安慰剂对照试验。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Homoeopathic drug pictures are developed by recording the symptomatic effects of homoeopathic remedies given to healthy volunteers (a 'proving'). In a double-blind randomized controlled trial we tested the hypothesis that individuals using an infinitesimal dilution of Belladonna (thirtieth potency, C30) would record more true symptoms, on a questionnaire that contained both true and false Belladonna proving symptoms, than those receiving placebo. 60 volunteers entered the study and 47 completed data collection. We were unable to distinguish between Belladonna C30 and placebo using our primary outcome measure. For the secondary outcome measure we analysed the number of individuals who proved to the remedy according to our predefined criteria: 4 out of 19 proved in the Belladonna C30 group and 1 out of 27 in the placebo group (difference not statistically significant). This pilot study does not demonstrate a clear proving reaction for Belladonna C30 versus placebo, but indicates how the question might be further investigated.
机译:顺势疗法药物图片是通过记录对健康志愿者的顺势疗法药物的症状影响而开发的(“证明”)。在一项双盲随机对照试验中,我们检验了以下假设:使用含有颠茄的无限稀释液的人(第三十效价,C30),在包含真颠茄实证和虚假颠茄实证的问卷上,其真实症状要比接受安慰剂的人多。 60名志愿者进入研究,完成了47项数据的收集。使用我们的主要疗效指标,我们无法区分颠茄C30和安慰剂。对于次要结局指标,我们根据我们预先定义的标准分析了证明可以治愈的个体数量:在颠茄C30组中,有19名患者中有4名,在安慰剂组中,有27名患者中的1名(差异无统计学意义)。这项初步研究并未证明颠茄C30与安慰剂有明确的反应,但指出了如何进一步研究该问题。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号